Fate Therapeutics, Inc. (FATE) on Course to Address Hematologic Malignancies ...
March 26, 2015 (www.investorideas.com newswire) It's nearly impossible to list all the ways in which stem cell exploration is important because the usefulness of these cells is virtually limitless. Stem cells have the potential to treat a huge range of ...
InvestorIdeas.com (press release) - Thu, 26 Mar 2015 11:11



Cancer in Cell Therapy's Crosshairs
Other hematologic malignancies are attractive targets as well. According to bone marrow transplant research, these types of tumors are easily accessible by T cells. Dr. Maus adds, “CAR-modified T cells can form memory, which means there is potential ...
Genetic Engineering & Biotechnology News - Tue, 31 Mar 2015 13:02

MEI Pharma Receives $7.50 Consensus PT from Analysts (NASDAQ:MEIP)
Pracinostat is an orally available histone deacetylase (NASDAQ:MEIP) inhibitor that is being developed for advanced hematologic diseases such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Receive News & Ratings for MEI ...
WKRB News - Mon, 30 Mar 2015 10:48

Infinity Exercises Option to Buy Out All Future Royalty Obligations to Takeda ...
“Our decision to exercise this option underscores Infinity's belief in the potential of duvelisib to be a first-in-class dual inhibitor of PI3K-delta,gamma for the treatment of a broad range of hematologic malignancies, or blood cancers, as we continue ...
MarketWatch - Tue, 31 Mar 2015 06:30



Small Benefit of Follow-Up Imaging in DLBCL Comes With High Costs
... patients following complete remission would reduce costs and is unlikely to adversely impact clinical outcomes of patients with DLBCL,” wrote Scott F. Huntington, MD, of the division of hematology-oncology at the University of Pennsylvania, and ...
Cancer Network - Mon, 30 Mar 2015 13:48

Comparable outcomes post allogeneic hematopoietic cell transplant for patients ...
Disease-related variables comprised characterization as de novo or sAML and cytogenetic risk at diagnosis. Patients with sAML were sub-grouped as having emerged from solid tumors, MDS or other hematologic malignancies, and the management of the ...
Nature.com - Mon, 30 Mar 2015 06:30

EMA validates MAA for Zinbryta to treat multiple sclerosis
The European Medicines Agency (EMA) has validated the Biogen and AbbVie's Marketing Authorisation Application (MAA) for Zinbryta (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU).
pharmabiz.com - Tue, 31 Mar 2015 04:29

Selvita Initiates IND-enabling Studies for its First-In-Class PIM/FLT3 Inhibitor
Aptuit has significant experience and expertise in the oncology disease area, in both hematologic and solid tumors, and multiple mechanisms of action, including tyrosine-kinase inhibitors. More info: www.aptuit.com. About Selvita Selvita is a drug ...
EIN News (press release) - Tue, 31 Mar 2015 08:00


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014